Neurochemical and Behavioral Effects of Synthetic Cathinones
Neurochemical and Behavioral Effects of Synthetic Cathinones
批准号:
9256450
负责人:
ANNETTE FLECKENSTEIN
金额:
$33.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-05-01 至 2021-04-30
关键词:
AcuteAdolescentAdolescent and Young AdultAgeAmphetamine AbuseBehavioralChemicalsClassificationCocaineCognitive deficitsDataDevelopmentDopamineDrug ExposureExposure toGlutamatesLaboratoriesLiteratureMethamphetamineModelingNeuronsNeuropeptidesNeurotensinParkinson DiseasePharmaceutical PreparationsPharmacology and ToxicologyProcessPublic HealthPublishingRattusReactive Oxygen SpeciesReportingSelf-AdministeredSynapsesTestingToxic effectanalogbasecathinonedopamine transporterdopaminergic neuronecstasyfunctional outcomesin vivomonoaminemonomethylpropionneurochemistryneurotoxicneurotoxicitynoveloperationpsychostimulantpublic health relevancestimulant abusetrendvesicular monoamine transporter 2young adult
中文摘要
描述(由申请人提供):滥用越来越多的结构多样的合成卡西酮是一个严重的公共卫生问题。这些制剂的滥用令人关切的原因有很多,包括滥用甲基苯丙胺和亚甲二氧基甲基苯丙胺等结构上相关的制剂可造成持续的神经化学和认知缺陷。因此,一些合成卡西酮可能同样会造成有害影响。然而,令人惊讶的是,很少有人知道这些药物对单胺能神经元功能的持续影响。在评估合成卡西酮的影响时,一个重要的考虑因素是,随着越来越多的此类药剂被禁止,非法操作引入了化学上新颖的替代品,以逃避监管限制。因此,如PAR 14-106中所述,重要的是开发常见合成卡西酮与转运蛋白等实体的相互作用谱,以便根据其潜在的滥用倾向和毒性谱对其进行分类。这样的模板也将B用于预测这些新化合物在不同发育阶段的影响,这是本PAR的另一个重要焦点。作为这个模板的贡献者之一,我们将测试这一假设,即多巴胺转运蛋白(DAT)和囊泡单胺转运蛋白-2(VMAT 2)功能的差异性改变预测合成卡西酮和相关药物的持久性神经化学,突触后和功能后果的差异;初始模拟暴露的发育阶段的影响。这将通过完成以下目标进行测试:1)评价非偶然暴露于三种已确定类别的合成卡西酮(甲氧麻黄酮、甲卡西酮和3,4-亚甲基二氧基吡咯戊酮)中的每一种对DAT和VMAT 2定位和功能的急性影响。我们将使用青少年和年轻成年大鼠进行这些研究,我们已经确定这些转运蛋白的功能可以作为年龄的函数进行差异调节。此外,我们将评估这些药物对已证明有助于精神兴奋剂诱导的神经毒性的参数的影响,包括活性物质形成和谷氨酸释放。2)研究药物诱导的单胺转运蛋白功能改变与行为和神经化学功能结局之间的关系,包括这些药物将:a)引起持续性单胺能缺陷; B)改变神经降压素水平,以及c)自我给药的可能性。如果自我管理,我们将评估随之而来的持续性神经化学效应,因为最近的研究从别人,我们证明了重要的区别之间的影响,应急和非应急兴奋剂暴露。3)评价合成卡西酮彼此、可卡因、METH和/或MDMA联合给药对多巴胺能神经元的持续神经化学影响的持续影响。其他人和我们已经证明,双重或连续暴露于精神兴奋剂可以深刻地改变他们的神经毒性档案,因此这个问题将进行评估。
英文摘要
DESCRIPTION (provided by applicant): The abuse of an increasing number of structurally diverse synthetic cathinones is a serious public health problem. The abuse of these agents is of concern for many reasons; including the fact that abuse of structurally related agents such as methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) can cause persistent neurochemical and cognitive deficits. Thus, it is likely that some synthetic cathinones might likewise cause detrimental effects. Still, surprisingly little is known concerning the persistent impact of these agents on monoaminergic neuronal function. An important consideration in evaluating the impact of synthetic cathinones is that as increasing numbers of these agents are banned, illicit operations introduce chemically novel replacements to evade regulatory restrictions. Thus, as described in PAR 14-106, it is important to develop interaction profiles of common synthetic cathinones with entities such as transporters in order to classify them according to their potential abuse liability and toxicity profiles. Such templates will also b useful to anticipate the impact of these novel compounds at various developmental stages, another important focus of this PAR. As one contributor to this template, we will test the hypothesis that differential alterations in dopamine transporter (DAT) and vesicular monoamine transporter-2 (VMAT2) function predict differences in the persistent neurochemical, post-synaptic and functional consequences of synthetic cathinones and related agents; an effect impacted by the developmental stage of initial analog exposure. This will be tested by completing the following aims: 1) Evaluate the acute impact of non-contingent exposure to representatives of each of three established classes of synthetic cathinones (mephedrone, methcathinone and 3,4-methylenedioxypyrovalerone) on DAT and VMAT2 localization and function. We will conduct these studies using both adolescent and young adult rats as others and we have established that these transporters' functions can be differentially regulated as a function of age. Additionally, we will evaluate the impact of these agents on parameters demonstrated to contribute to psychostimulant-induced neurotoxicity, including reactive species formation and glutamate release. 2) Investigate the relationship between drug-induced alterations in monoamine transporter function with behavioral and neurochemical functional outcomes, including the likelihood that these agents will: a) cause persistent monoaminergic deficits; b) alter neurotensin levels, and c) be self-administrated. If self-administered, we will evaluate consequent persistent neurochemical effects as recent studies from others and we demonstrate important distinctions between the impact of contingent and non-contingent stimulant exposure. 3) Evaluate the persistent impact of co-administration of synthetic cathinones with each other, cocaine, METH and/or MDMA on the persistent neurochemical impact on dopaminergic neurons. Others and we have demonstrated that dual or sequential exposure to psychostimulants can profoundly alter their neurotoxic profiles, and thus this issue will be evaluated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Psychostimulants, Attention Deficit and Basal Ganglia Disorders
-
批准号:10441781
-
项目类别:
-
资助金额:$19.2万
-
财政年份:2022
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Neurochemical and Behavioral Effects of Synthetic Cathinones
-
批准号:9921319
-
项目类别:
-
资助金额:$33.53万
-
财政年份:2016
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Neurochemical and Behavioral Effects of Synthetic Cathinones
-
批准号:9471810
-
项目类别:
-
资助金额:$33.53万
-
财政年份:2016
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Career Development Award
-
批准号:8247059
-
项目类别:
-
资助金额:$13.22万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
K02 Application
-
批准号:7031032
-
项目类别:
-
资助金额:$12.82万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Career Development Award
-
批准号:8447526
-
项目类别:
-
资助金额:$13.22万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
K02 Application
-
批准号:7618003
-
项目类别:
-
资助金额:$12.93万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Career Development Award
-
批准号:8637027
-
项目类别:
-
资助金额:$13.22万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Career Development Award
-
批准号:7738562
-
项目类别:
-
资助金额:$13.22万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Career Development Award
-
批准号:8022953
-
项目类别:
-
资助金额:$13.22万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
K02 Application
-
批准号:7392149
-
项目类别:
-
资助金额:$12.93万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
K02 Application
-
批准号:7217484
-
项目类别:
-
资助金额:$12.93万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
K02 Application
-
批准号:6899602
-
项目类别:
-
资助金额:$12.45万
-
财政年份:2005
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
DEVELOPMENTAL REFRACTORINESS
-
批准号:8037144
-
项目类别:
-
资助金额:$15.78万
-
财政年份:2001
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
DEVELOPMENTAL REFRACTORINESS
-
批准号:8375670
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2001
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
DEVELOPMENTAL REFRACTORINESS
-
批准号:7794886
-
项目类别:
-
资助金额:$15.47万
-
财政年份:2001
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
DEVELOPMENTAL REFRACTORINESS
-
批准号:8223700
-
项目类别:
-
资助金额:$15.76万
-
财政年份:2001
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
METHAMPHETAMINE AND DOPAMINE TRANSPORTERS
-
批准号:6342270
-
项目类别:
-
资助金额:$11.21万
-
财政年份:1998
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Psychostimulants and Monoamine Transporters
-
批准号:6702557
-
项目类别:
-
资助金额:$22.43万
-
财政年份:1998
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
Psychostimulants and Monoamine Transporters
-
批准号:6868057
-
项目类别:
-
资助金额:$22.43万
-
财政年份:1998
-
负责人:ANNETTE FLECKENSTEIN
-
依托单位:
海外基金